ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!GOSS Company Profile and Key Details
Gossamer Bio, Inc.
GOSS Stock Price Chart
Stock Price Today
Gossamer Bio, Inc. (GOSS) stock declined over -8.50%, trading at $1.40 on NASDAQ, down from the previous close of $1.53. The stock opened at $1.53, fluctuating between $1.40 and $1.54 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Company Information
| Employees | 135 |
| Beta | 1.81 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Gossamer Bio, Inc. (NASDAQ: GOSS) stock price is $1.40 in the last trading session. During the trading session, GOSS stock reached the peak price of $1.54 while $1.40 was the lowest point it dropped to. The percentage change in GOSS stock occurred in the recent session was -8.5% while the dollar amount for the price change in GOSS stock was -$0.13.
The NASDAQ listed GOSS is part of Biotechnology industry that operates in the broader Healthcare sector. Gossamer Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Bryan Giraudo
Chief Operating Officer & Chief Financial Officer
Mr. Mario Orlando
Senior Vice President of Commercial New Product Planning
Mr. Faheem Hasnain
Co-Founder, Chief Executive Officer, Pres & Chairman
Mr. Christian Waage
Executive Vice President of Technical Operations & Admin.
Dr. Laura L. Carter Ph.D.
Chief Scientific Officer
Mr. Matt Cravets
Senior Vice President of Biometrics
Mr. Jeff Boerneke
Gen. Counsel & Sec.
Ms. Caryn L. Peterson
Executive Vice President of Regulatory Affairs
Dr. Richard Aranda M.D.
Chief Medical Officer
Ms. Deanna Weber
Senior Vice President of HR
Dr. Lisa Elizabeth Nolan Ph.D.
MD & Pres of Gossamer Bio Ireland
GOSS's closing price is 180.56% higher than its 52-week low of $0.50 where as its distance from 52-week high of $1.60 is -12.5%.
Number of GOSS employees currently stands at 135.
Official Website of GOSS is: https://www.gossamerbio.com
GOSS could be contacted at phone 858 684 1300 and can also be accessed through its website. GOSS operates from 3013 Science Park Road, San Diego, CA 92121, United States.
GOSS stock volume for the day was 1.58M shares. The average number of GOSS shares traded daily for last 3 months was 1.62M.
The market value of GOSS currently stands at $317.25M with its latest stock price at $1.40 and 226.6M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com